Demonstration of [3H]cyclazocine binding to multiple opiate receptor sites

R. S. Zukin, S. R. Zukin

Research output: Contribution to journalArticle

Abstract

Interaction of the psychotomimetic opiate cyclazocine with multiple receptor sites has been demonstrated biochemically. Cyclazocine has been postulated to interact with μ, κ, and σ opiate receptors (Martin et al., J. Pharmacol. Exp. Ther. 197:517-532 (1976).) In an effort to understand the molecular mechanisms involved in the neuropharmacological actions of this and closely related opiates the authors have studied the binding of [3H]cyclazocine to rat brain homogenates. Specific binding, defined as total binding minus binding in the presence of 10 μM nonradioactive cyclazocine, constitutes approximately 92% of total binding at 1.0 nM 3H-labeled ligand and 67% of total binding at 100 nM 3H-labeled ligand. Scatchard analyses utilizing various competing drugs reveal the apparent interaction of this drug with three distinct binding sites characterized by affinities of 0.2 nM, 11 nM, and 70 nM (50 nM Tris-HCl buffer, pH 7.4 at 4°). In contrast, many radiolabeled classical opiates and opioid peptides have been reported to exhibit biphasic binding but do not exhibit binding to a site of such low affinity. The high- and low-affinity [3H]cyclazocine sites exhibit differential sensitivities to sodium and also to the selective sulfhydryl reagent N-ethylmaleimide. In addition, all three sites exhibit greater than 50% loss of specific binding following incubation with trypsin (5 μg/ml) for 15 min at room temperature, and greater than 80% loss of specific binding following incubation at 60° for 15 min in the absence of added reagents. Together, these findings indicate that all three sites have a protein-like component. Competition analyses involving rank order determinations for a series of opiates and other drugs indicate that the cyclazocine binding sites represent, in order of decreasing affinity, the classical opiate receptor (the putative 'μ' receptor), a second as yet uncharacterized opiate binding site, and the specific [3H]phencyclidine binding site. Specific [3H]phencyclidine binding can be displaced by cyclazocine (IC50 = 350 nM) and by related benzomorphans, but not by classical opiates such as morphine or naloxone. The authors thus propose a common binding site in rat nervous tissue for phencyclidine and some of the benzomorphan opiates.

Original languageEnglish (US)
Pages (from-to)246-254
Number of pages9
JournalMolecular Pharmacology
Volume20
Issue number2
StatePublished - 1981
Externally publishedYes

Fingerprint

Cyclazocine
Opiate Alkaloids
Opioid Receptors
Phencyclidine
Binding Sites
Benzomorphans
Opioid Peptides
Ligands
Nerve Tissue
Sulfhydryl Reagents
Tromethamine
Ethylmaleimide
Naloxone
Drug Interactions
Pharmaceutical Preparations
Trypsin
Morphine
Inhibitory Concentration 50
Sodium
Temperature

ASJC Scopus subject areas

  • Pharmacology

Cite this

Demonstration of [3H]cyclazocine binding to multiple opiate receptor sites. / Zukin, R. S.; Zukin, S. R.

In: Molecular Pharmacology, Vol. 20, No. 2, 1981, p. 246-254.

Research output: Contribution to journalArticle

Zukin, R. S. ; Zukin, S. R. / Demonstration of [3H]cyclazocine binding to multiple opiate receptor sites. In: Molecular Pharmacology. 1981 ; Vol. 20, No. 2. pp. 246-254.
@article{8b2caa2e215d4b65bbdc91851ed887b5,
title = "Demonstration of [3H]cyclazocine binding to multiple opiate receptor sites",
abstract = "Interaction of the psychotomimetic opiate cyclazocine with multiple receptor sites has been demonstrated biochemically. Cyclazocine has been postulated to interact with μ, κ, and σ opiate receptors (Martin et al., J. Pharmacol. Exp. Ther. 197:517-532 (1976).) In an effort to understand the molecular mechanisms involved in the neuropharmacological actions of this and closely related opiates the authors have studied the binding of [3H]cyclazocine to rat brain homogenates. Specific binding, defined as total binding minus binding in the presence of 10 μM nonradioactive cyclazocine, constitutes approximately 92{\%} of total binding at 1.0 nM 3H-labeled ligand and 67{\%} of total binding at 100 nM 3H-labeled ligand. Scatchard analyses utilizing various competing drugs reveal the apparent interaction of this drug with three distinct binding sites characterized by affinities of 0.2 nM, 11 nM, and 70 nM (50 nM Tris-HCl buffer, pH 7.4 at 4°). In contrast, many radiolabeled classical opiates and opioid peptides have been reported to exhibit biphasic binding but do not exhibit binding to a site of such low affinity. The high- and low-affinity [3H]cyclazocine sites exhibit differential sensitivities to sodium and also to the selective sulfhydryl reagent N-ethylmaleimide. In addition, all three sites exhibit greater than 50{\%} loss of specific binding following incubation with trypsin (5 μg/ml) for 15 min at room temperature, and greater than 80{\%} loss of specific binding following incubation at 60° for 15 min in the absence of added reagents. Together, these findings indicate that all three sites have a protein-like component. Competition analyses involving rank order determinations for a series of opiates and other drugs indicate that the cyclazocine binding sites represent, in order of decreasing affinity, the classical opiate receptor (the putative 'μ' receptor), a second as yet uncharacterized opiate binding site, and the specific [3H]phencyclidine binding site. Specific [3H]phencyclidine binding can be displaced by cyclazocine (IC50 = 350 nM) and by related benzomorphans, but not by classical opiates such as morphine or naloxone. The authors thus propose a common binding site in rat nervous tissue for phencyclidine and some of the benzomorphan opiates.",
author = "Zukin, {R. S.} and Zukin, {S. R.}",
year = "1981",
language = "English (US)",
volume = "20",
pages = "246--254",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "2",

}

TY - JOUR

T1 - Demonstration of [3H]cyclazocine binding to multiple opiate receptor sites

AU - Zukin, R. S.

AU - Zukin, S. R.

PY - 1981

Y1 - 1981

N2 - Interaction of the psychotomimetic opiate cyclazocine with multiple receptor sites has been demonstrated biochemically. Cyclazocine has been postulated to interact with μ, κ, and σ opiate receptors (Martin et al., J. Pharmacol. Exp. Ther. 197:517-532 (1976).) In an effort to understand the molecular mechanisms involved in the neuropharmacological actions of this and closely related opiates the authors have studied the binding of [3H]cyclazocine to rat brain homogenates. Specific binding, defined as total binding minus binding in the presence of 10 μM nonradioactive cyclazocine, constitutes approximately 92% of total binding at 1.0 nM 3H-labeled ligand and 67% of total binding at 100 nM 3H-labeled ligand. Scatchard analyses utilizing various competing drugs reveal the apparent interaction of this drug with three distinct binding sites characterized by affinities of 0.2 nM, 11 nM, and 70 nM (50 nM Tris-HCl buffer, pH 7.4 at 4°). In contrast, many radiolabeled classical opiates and opioid peptides have been reported to exhibit biphasic binding but do not exhibit binding to a site of such low affinity. The high- and low-affinity [3H]cyclazocine sites exhibit differential sensitivities to sodium and also to the selective sulfhydryl reagent N-ethylmaleimide. In addition, all three sites exhibit greater than 50% loss of specific binding following incubation with trypsin (5 μg/ml) for 15 min at room temperature, and greater than 80% loss of specific binding following incubation at 60° for 15 min in the absence of added reagents. Together, these findings indicate that all three sites have a protein-like component. Competition analyses involving rank order determinations for a series of opiates and other drugs indicate that the cyclazocine binding sites represent, in order of decreasing affinity, the classical opiate receptor (the putative 'μ' receptor), a second as yet uncharacterized opiate binding site, and the specific [3H]phencyclidine binding site. Specific [3H]phencyclidine binding can be displaced by cyclazocine (IC50 = 350 nM) and by related benzomorphans, but not by classical opiates such as morphine or naloxone. The authors thus propose a common binding site in rat nervous tissue for phencyclidine and some of the benzomorphan opiates.

AB - Interaction of the psychotomimetic opiate cyclazocine with multiple receptor sites has been demonstrated biochemically. Cyclazocine has been postulated to interact with μ, κ, and σ opiate receptors (Martin et al., J. Pharmacol. Exp. Ther. 197:517-532 (1976).) In an effort to understand the molecular mechanisms involved in the neuropharmacological actions of this and closely related opiates the authors have studied the binding of [3H]cyclazocine to rat brain homogenates. Specific binding, defined as total binding minus binding in the presence of 10 μM nonradioactive cyclazocine, constitutes approximately 92% of total binding at 1.0 nM 3H-labeled ligand and 67% of total binding at 100 nM 3H-labeled ligand. Scatchard analyses utilizing various competing drugs reveal the apparent interaction of this drug with three distinct binding sites characterized by affinities of 0.2 nM, 11 nM, and 70 nM (50 nM Tris-HCl buffer, pH 7.4 at 4°). In contrast, many radiolabeled classical opiates and opioid peptides have been reported to exhibit biphasic binding but do not exhibit binding to a site of such low affinity. The high- and low-affinity [3H]cyclazocine sites exhibit differential sensitivities to sodium and also to the selective sulfhydryl reagent N-ethylmaleimide. In addition, all three sites exhibit greater than 50% loss of specific binding following incubation with trypsin (5 μg/ml) for 15 min at room temperature, and greater than 80% loss of specific binding following incubation at 60° for 15 min in the absence of added reagents. Together, these findings indicate that all three sites have a protein-like component. Competition analyses involving rank order determinations for a series of opiates and other drugs indicate that the cyclazocine binding sites represent, in order of decreasing affinity, the classical opiate receptor (the putative 'μ' receptor), a second as yet uncharacterized opiate binding site, and the specific [3H]phencyclidine binding site. Specific [3H]phencyclidine binding can be displaced by cyclazocine (IC50 = 350 nM) and by related benzomorphans, but not by classical opiates such as morphine or naloxone. The authors thus propose a common binding site in rat nervous tissue for phencyclidine and some of the benzomorphan opiates.

UR - http://www.scopus.com/inward/record.url?scp=0019393697&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019393697&partnerID=8YFLogxK

M3 - Article

C2 - 6272083

AN - SCOPUS:0019393697

VL - 20

SP - 246

EP - 254

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

IS - 2

ER -